Regenxbio Inc (RGNX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$7.16

+0.28 (+4.07%)

Market Cap: $479.26M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

46%(18/39)

Avg Surprise

+0.01%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-1.30

Range$-1.63 - $-0.89

9 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-1.22-6.1%

60d ago$-0.97-34.4%

30d ago$-1.27-2.5%

7d ago$-1.27-2.5%

Current$-1.30

Revenue Consensus

$15M

Range$6M - $51M

9 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.67

Range$-2.04 - $1.79

9 analysts

Revenue Consensus

$27M

Range$-10593630 - $162M

10 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.67	$-2.04 - $1.79	-	-	9	-	-
Sep 30, 2026Sep 26EST	-	$-1.30	$-1.63 - $-0.89	-	-	9	4 2 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$0.43	$0.12	$-1.23 - $0.73	+258.33%	Beat	7	0 1 30d	+131.2%
Mar 31, 2026Mar 26 Reported May 14, 2026Reported May 14	$-1.72	$-1.41	$-1.58 - $-1.23	-21.99%	Miss	5	0 4 30d	-1533.3%
Dec 31, 2025Dec 25 Reported Mar 5, 2026Reported Mar 5	$-1.30	$-0.72	$-1.65 - $0.43	-80.71%	Miss	8	0 2 30d	-28.7%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$-1.20	$-1.30	$-1.68 - $-0.89	+7.69%	Beat	6	0 1 30d	-2.6%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$-1.38	$-1.13	$-1.34 - $-0.75	-22.12%	Miss	6	2 2 30d	-31.4%
Mar 31, 2025Mar 25 Reported May 12, 2025Reported May 12	$0.12	N/A	-	-75.51%	Miss	5	1 0 30d	+109.0%
Dec 31, 2024Dec 24 Reported Mar 13, 2025Reported Mar 13	$-1.01	$-1.08	$-1.33 - $-0.46	+6.86%	Beat	7	1 0 30d	+29.4%
Sep 30, 2024Sep 24 Reported Nov 6, 2024Reported Nov 6	$-1.17	$-1.10	$-1.28 - $-1.05	-6.36%	Miss	9	No revisions (30d)	+17.0%
Jun 30, 2024Jun 24 Reported Aug 1, 2024Reported Aug 1	$-1.05	$-1.31	$-1.41 - $-1.11	+19.85%	Beat	8	No revisions (30d)	+36.7%
Mar 31, 2024Mar 24 Reported May 8, 2024Reported May 8	$-1.34	$-1.26	$-1.50 - $-1.11	-6.35%	Miss	10	No revisions (30d)	+12.4%
Dec 31, 2023Dec 23 Reported Feb 27, 2024Reported Feb 27	$-1.43	$-1.27	$-1.52 - $-0.77	-12.60%	Miss	9	No revisions (30d)	-3.6%
Sep 30, 2023Sep 23 Reported Nov 8, 2023Reported Nov 8	$-1.41	$-1.52	$-1.74 - $-1.26	+7.24%	Beat	8	No revisions (30d)	+19.4%
Jun 30, 2023Jun 23 Reported Aug 2, 2023Reported Aug 2	$-1.66	$-1.21	$-1.55 - $-1.20	-37.19%	Miss	6	No revisions (30d)	-5.1%
Mar 31, 2023Mar 23 Reported May 3, 2023Reported May 3	$-1.53	$-1.41	$-1.77 - $-1.28	-8.51%	Miss	6	No revisions (30d)	+14.5%
Dec 31, 2022Dec 22 Reported Feb 28, 2023Reported Feb 28	$-1.38	$-1.23	$-1.67 - $-0.22	-12.20%	Miss	7	No revisions (30d)	-120.7%
Sep 30, 2022Sep 22 Reported Nov 3, 2022Reported Nov 3	$-1.75	$-1.46	$-1.56 - $-1.37	-19.86%	Miss	7	No revisions (30d)	-27.7%
Jun 30, 2022Jun 22 Reported Aug 3, 2022Reported Aug 3	$-1.58	$-1.54	$-1.64 - $-1.36	-2.60%	Miss	7	0 1 30d	-16.2%
Mar 31, 2022Mar 22 Reported May 4, 2022Reported May 4	$-1.79	$-1.28	$-1.39 - $-1.23	-39.84%	Miss	5	No revisions (30d)	-49.2%
Dec 31, 2021Dec 21 Reported Mar 1, 2022Reported Mar 1	$6.67	$4.71	$-1.31 - $9.39	+41.61%	Beat	6	No revisions (30d)	+637.9%
Sep 30, 2021Sep 21 Reported Nov 2, 2021Reported Nov 2	$-1.37	$-1.12	$-1.55 - $0.00	-22.32%	Miss	6	1 0 30d	-426.2%
Jun 30, 2021Jun 21 Reported Aug 9, 2021Reported Aug 9	$-1.36	$-1.15	$-1.70 - $-0.93	-18.26%	Miss	7	No revisions (30d)	-49.5%
Mar 31, 2021Mar 21 Reported May 5, 2021Reported May 5	$-1.20	$-1.30	$-1.63 - $-0.90	+7.69%	Beat	7	No revisions (30d)	-11.1%
Dec 31, 2020Dec 20 Reported Mar 1, 2021Reported Mar 1	$-1.24	$-0.43	$-1.70 - $4.10	-188.37%	Miss	7	No revisions (30d)	-72.2%
Sep 30, 2020Sep 20 Reported Nov 4, 2020Reported Nov 4	$0.42	N/A	-	+141.58%	Beat	6	1 0 30d	+144.7%
Jun 30, 2020Jun 20 Reported Aug 6, 2020Reported Aug 6	$-0.91	$-0.93	$-1.07 - $-0.85	+2.15%	Beat	4	No revisions (30d)	-9.6%
Mar 31, 2020Mar 20 Reported May 7, 2020Reported May 7	$-1.08	$-0.87	$-1.02 - $-0.60	-24.14%	Miss	3	No revisions (30d)	-21.3%
Dec 31, 2019Dec 19 Reported Feb 26, 2020Reported Feb 26	$-0.72	$-0.95	$-1.19 - $0.25	+24.21%	Beat	5	No revisions (30d)	-754.5%
Sep 30, 2019Sep 19 Reported Nov 5, 2019Reported Nov 5	$-0.94	$-0.24	$-1.09 - $-0.24	-291.67%	Miss	5	No revisions (30d)	-67.9%
Jun 30, 2019Jun 19 Reported Aug 7, 2019Reported Aug 7	$-0.83	$-0.77	$-0.85 - $0.09	-7.79%	Miss	5	1 0 30d	-376.7%
Mar 31, 2019Mar 19 Reported May 7, 2019Reported May 7	$-0.89	$-0.89	$-0.98 - $-0.77	+0.00%	Beat	4	No revisions (30d)	-129.3%
Dec 31, 2018Dec 18 Reported Feb 27, 2019Reported Feb 27	$0.11	N/A	-	+132.35%	Beat	4	1 0 30d	+121.6%
Sep 30, 2018Sep 18 Reported Nov 7, 2018Reported Nov 7	$-0.56	$-0.81	$-0.86 - $0.31	+30.86%	Beat	3	No revisions (30d)	+16.4%
Jun 30, 2018Jun 18 Reported Aug 8, 2018Reported Aug 8	$0.30	$0.56	-	-46.43%	Miss	2	No revisions (30d)	+163.8%
Mar 31, 2018Mar 18 Reported May 8, 2018Reported May 8	$3.04	$1.07	$-0.88 - $1.63	+184.11%	Beat	5	No revisions (30d)	+470.7%
Dec 31, 2017Dec 17 Reported Mar 6, 2018Reported Mar 6	$-0.51	$-0.82	$-0.92 - $-0.67	+37.80%	Beat	5	No revisions (30d)	+31.1%
Sep 30, 2017Sep 17 Reported Nov 8, 2017Reported Nov 8	$-0.67	$-0.73	$-0.80 - $-0.66	+8.22%	Beat	4	No revisions (30d)	-
Jun 30, 2017Jun 17 Reported Aug 8, 2017Reported Aug 8	$-0.47	$-0.80	$-0.81 - $-0.69	+41.25%	Beat	2	No revisions (30d)	-
Mar 31, 2017Mar 17 Reported May 9, 2017Reported May 9	$-0.82	$-0.76	-	-7.89%	Miss	-	-	-
Dec 31, 2016Dec 16 Reported Mar 7, 2017Reported Mar 7	$-0.74	$-0.75	-	+1.33%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-1.89	EV/EBITDA	N/A
Price/FCF	-1.51x	FCF Yield	-66.02%
Profitability
Profit Margin	-112.60%	Operating Margin	27.10%
ROE	-137.60%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	-3.91x
Current Ratio	2.86x	Quick Ratio	2.86x
Trading Statistics
Beta	1.13	Avg Volume	1.57M
52-Week High	$16.19	52-Week Low	$5.46

Technical Indicators Dashboard

Moving Averages

SMA 10$7.55

SMA 20$7.58

SMA 50$8.85

SMA 200$9.58

EMA 10$7.46

EMA 20$7.71

EMA 50$8.47

EMA 200$9.34

MACD

Line: -0.39Signal: -0.41Hist: 0.03

ADX

ADX: 16.8+DI: 18.8-DI: 29.4

Aroon & PSAR

Aroon Up4.0

Aroon Down96.0

PSAR$8.23

Bollinger Bands

Upper Band$8.26

Lower Band$6.90

%B Position1799%(Upper)

Band Width0.19

RSI (14-Day)

Neutral

39.4

Momentum Oscillators

Stoch %K13.9

Stoch %D29.0

Williams %R-76.2

ROC (10d)-3.5%

Momentum-0.26

CCI (20d)-124.4

MFI (14d)49.2

Volatility Measures

ATR (14d)$0.54(7.5%)

StdDev (20d)0.34

Hist Vol61.0%(High)

Volume Flow

VWAP$7.09

OBV8.2M

AD Line-8.4M

CMF (20d)-0.267

Volume Metrics

Avg Vol (20d)1.6M

Vol Ratio0.8x

VWMA (20d)$7.61

Pivot Points

R3$7.59

R2$7.41

R1$7.15

Pivot Point$6.97

S1$6.71

S2$6.53

S3$6.27

Advanced Oscillators

TSI-20.59

Ultimate Osc44.1

KST-146.09

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$108.02M	$6.39M	$30.34M	$29.73M	$21.36M	$89.01M	$21.21M	$24.20M	$22.30M	$15.62M	$22.21M	$28.91M
Cost of Revenue	$0	$0	$5.93M	$0	$0	$0	$-5,000,000	$0	$0	$0	$11.24M	$12.39M
Gross Profit	$108.02M	$6.39M	$30.34M	$29.73M	$21.36M	$89.01M	$26.21M	$24.20M	$22.30M	$15.62M	$10.97M	$16.53M

Operating Expenses	$78.76M	$89.75M	$87.97M	$82.14M	$84.64M	$76.89M	$77.58M	$86.28M	$78.33M	$79.48M	$74.88M	$81.49M
R&D	$56.09M	$57.34M	$59.61M	$56.10M	$59.50M	$53.09M	$50.38M	$54.43M	$48.87M	$54.84M	$55.68M	$58.18M
SG&A	$21.62M	$21.31M	$22.38M	$20.25M	$19.88M	$20.35M	$20.05M	$19.42M	$18.86M	$18.29M	$19.08M	$23.08M
Operating Income	$29.26M	$-83,362,000	$-57,636,000	$-52,411,000	$-63,278,000	$12.13M	$-51,368,000	$-62,078,000	$-56,037,000	$-63,863,000	$-63,903,000	$-64,960,000

Interest Income	$1.22M	$2.00M	$2.75M	$3.62M	$3.38M	$2.50M	$9.52M	$3.28M	$3.47M	$2.47M	$2.37M	$4.66M
Interest Expense	$7.79M	$8.71M	$12.28M	$13.17M	$10.99M	$8.57M	$9.42M	$820,000	$449,000	$1.97M	$1.36M	$1.62M
Income Before Tax	$22.71M	$-90,051,000	$-67,149,000	$-61,941,000	$-70,871,000	$6.08M	$-51,186,000	$-59,597,000	$-52,989,000	$-63,330,000	$-63,041,000	$-61,868,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$22.71M	$-90,051,000	$-67,149,000	$-61,941,000	$-70,871,000	$6.08M	$-51,186,000	$-59,597,000	$-52,989,000	$-63,330,000	$-62,889,000	$-61,868,000

EBITDA	$32.59M	$-80,368,000	$-54,978,000	$-50,329,000	$-60,708,000	$15.04M	$-48,379,000	$-59,408,000	$-53,200,000	$-60,114,000	$-59,951,000	$-60,665,000
EBIT	$29.28M	$-83,346,000	$-57,618,000	$-52,392,000	$-63,257,000	$12.15M	$-51,285,000	$-62,053,000	$-56,008,000	$-63,826,000	$-64,044,000	$-64,904,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about RGNX

News

Form 8-K REGENXBIO Inc. For: Oct 14

REGENXBIO Inc. filed a Form 8-K on October 14, 2026, announcing the resignation of Kenneth T. Mills from its board of directors, effective October 21...

StreetInsider•Oct 16, 2026 6:40 AM ET10/16/26•Neutral

Mizuho sets USD 22.00 target for REGENXBIO stock

Mizuho has set a USD 22.00 price target for REGENXBIO (RGNX) stock, significantly higher than its current trading price. The company is preparing for an investor event on October 20, 2026...

ad-hoc-news.de•Oct 15, 2026 2:09 PM ET10/15/26•Bullish

Price-Driven Insight from (RGNX) for Rule-Based Strategy

This article provides a price-driven insight for Regenxbio Inc. (NASDAQ: RGNX), highlighting stable neutral readings in shorter horizons which could signal an easing of a long-term weak bias. It details exceptional...

Stock Traders Daily•Oct 13, 2026 6:38 PM ET10/13/26•Somewhat-Bearish

JPMorgan reports a passive stake above 5% in REGENXBIO (RGNX).

JPMorgan Chase & Co. has reported a passive beneficial ownership stake of 5.3% in REGENXBIO Inc. (RGNX), amounting to 3,560,915 shares, as of September 30...

Stock Titan•Oct 13, 2026 1:10 PM ET10/13/26•Neutral

Form SCHEDULE 13G REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO

JPMorgan Chase & Co. filed a Schedule 13G with the SEC, reporting beneficial ownership of 3,560,915 shares of REGENXBIO Inc. common stock...

StreetInsider•Oct 13, 2026 1:10 PM ET10/13/26•Neutral

RGNX Valuation and Fair Value

P/E: -1.9x
P/FCF: -1.5x
PEG: 0.3x
P/B: 5.3x

See GNG's fair value

RGNX Profitability: Margins, ROIC and FCF

Gross margin: 100.0%
Operating margin: 27.1%
Net margin: -112.6%
ROE: -137.6%
FCF margin: -143.1%
FCF yield: -66.0%

RGNX Competitors

Company	Ticker
Sight Sciences Inc	SGHT
Evotec SE ADR	EVO
Evolus Inc	EOLS
XOMA Corp	XOMA
Tactile Systems Technology Inc	TCMD
Senseonics Holdings, Inc. Common Stock	SENS
CytomX Therapeutics Inc	CTMX
AngioDynamics Inc	ANGO

Sector: Healthcare

RGNX Analyst Ratings

Consensus: Buy
Analysts: 11
Strong Buy: 3
Buy: 6
Hold: 2
Sell: 0
Strong Sell: 0

RGNX Bull Case vs Bear Case

Bull case

RGNX grew quarterly revenue 405.7% year over year.
81.8% of RGNX's analyst ratings are Buy or Strong Buy.

Bear case

RGNX has a -112.6% net profit margin.
RGNX beat EPS estimates in 37.5% of its last 8 reported quarters.

RGNX Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: 8.3%
EPS estimate (fiscal period ending Sep 30, 2026): $-1.30
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 4 up, 2 down

Frequently Asked Questions About RGNX

Does RGNX pay dividends?

Regenxbio Inc (RGNX) does not currently pay a regular dividend.

What is RGNX's market cap?

Regenxbio Inc (RGNX) has a market capitalization of $479.26M with a current stock price of $7.16.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In

Earnings

Performance (10Y)

Upcoming Estimates

Key Metrics

Technical Indicators Dashboard

Moving Averages

MACD

ADX

Aroon & PSAR

Bollinger Bands

RSI (14-Day)

Momentum Oscillators

Volatility Measures

Volume Flow

Volume Metrics

Pivot Points

Advanced Oscillators

Financial Data

Related GNG Research

News

Form 8-K REGENXBIO Inc. For: Oct 14

Mizuho sets USD 22.00 target for REGENXBIO stock

Price-Driven Insight from (RGNX) for Rule-Based Strategy

JPMorgan reports a passive stake above 5% in REGENXBIO (RGNX).

Form SCHEDULE 13G REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO

RGNX Valuation and Fair Value

RGNX Profitability: Margins, ROIC and FCF

RGNX Competitors

RGNX Analyst Ratings

RGNX Bull Case vs Bear Case

Bull case

Bear case

RGNX Earnings: Beat Rate and Next Report

Frequently Asked Questions About RGNX

Related stocks

Get full access to GNG Research